HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Genscript Biotech (1548.HK) - Inadequate Cognition Will Lead to Bad Investment Decisions

China Healthcare Weekly (Feb.17) - CXO Vs Pharma, Medical Insurance Account Reform, Time to Reflect

Fu Shou Yuan (1448.HK) - Some Points Worth the Attention

Shanghai Haohai Biological Technology (688366.CH/6826.HK)- Disappointing Earnings and Gloomy Outlook

Reform in China's Medical Service Industry: SOE-Run Hospitals Usher in a Critical Turning Point

WuXi AppTec (2359.HK/603259.CH) - Not the Time to Be Happy Even After a Positive Profit Alert

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Bottom-Up

Sonoscape Medical Corp / Equity Bottom-Up

<ul>
<li>We are optimistic about Sonoscape's 2022 annual results, which was an important turning year. Due to policy catalyst/China reopening, Sonoscape would maintain high growth in 2023, with relatively high certainty.</li>
<li>Sonoscape has established a high moat in the field of soft endoscopes. Even if new manufacturers enter this market, they are hard to affect the market pattern in short term.</li>
<li>Although the current valuation is not cheap, based on our forecast of its business lines, there's still growth space in valuation. Under positive momentum, this stock can be traded repeatedly.</li>
</ul>


We are optimistic about Sonoscape's 2022 annual results, which was an important turning year. Due to policy catalyst/China reopening, Sonoscape would maintain high growth in 2023, with relatively high certainty.
Sonoscape has established a high moat in the field of soft endoscopes. Even if new manufacturers enter this market, they are hard to affect the market pattern in short term.
Although the current valuation is not cheap, based on our forecast of its business lines, there's still growth space in valuation. Under positive momentum, this stock can be traded repeatedly.


Shenzhen Mindray Bio-Medical Electronics (300760 CH)

2023 High Conviction Update: Sonoscape Medical (300633.CH) - High Growth Is Expected to Continue